KLOW 80 mg

Four-Peptide Research Blend (GHK-Cu, BPC-157, TB-500, KPV)

In plain terms: This is a four-peptide blend combining separate compounds that are

each individually studied for tissue repair and inflammation pathways, letting

researchers observe how those pathways interact when studied together.

Compound classification: KLOW combines GHK-Cu (50mg), BPC-157 (10mg), TB-500

(10mg), and KPV (10mg) — four peptides studied across complementary tissue and

cellular-signaling research pathways.

Studied mechanism: Each component has an independently studied mechanism: GHK-

Cu (gene expression tied to collagen synthesis and antioxidant activity), BPC-157 (nitric oxide and growth-factor pathway research), TB-500 (actin dynamics research), and KPV (NF-κB and cytokine signaling research).

Research findings: Preclinical and in-vitro research has examined coordinated effects

across collagen production, angiogenesis, cell migration, and inflammatory signaling

markers when these components are studied together.

Effects reported in research literature:

Injection site reactions (in study subjects)

Localized warmth at application site

Gastrointestinal markers associated with the BPC-157 component

Research status: This is a compounded research blend; long-term safety and efficacy

data for the combined formulation remain under investigation.

Research Use Only: This compound is intended for laboratory research use only. It is

not a drug, dietary supplement, or consumer product, and is not for human or animal

consumption. Statements have not been evaluated by the FDA and are not intended to

diagnose, treat, cure, or prevent any disease.